Roshan Sethi1, Elliott Kozin2, Aaron Remenschneider2, Josh Meier2, Paul VanderLaan1, William Faquin3, Daniel Deschler2, Robert Frankenthaler4. 1. Harvard Medical School, Boston, MA. 2. Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary / Harvard Medical School, Boston, MA. 3. Department of Pathology, Massachusetts General Hospital, Boston, MA. 4. Division of Otolaryngology, Beth Israel Medical Center, Boston, MA; Department of Pathology, Beth Israel Medical Center, Boston, MA.
Abstract
OBJECTIVES/HYPOTHESIS: To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC). DATA SOURCES: PubMed. REVIEW METHODS: Literature search using the terms "Mammary analogue secretory carcinoma," "Mammary analog secretory carcinoma," and "MASC" to identify all relevant publications. RESULTS: MASC is an unusual and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical, and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. Many cases of MASC were discovered in archived cases previously classified as acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma not otherwise specified. CONCLUSION: MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity.
OBJECTIVES/HYPOTHESIS: To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC). DATA SOURCES: PubMed. REVIEW METHODS: Literature search using the terms "Mammary analogue secretory carcinoma," "Mammary analog secretory carcinoma," and "MASC" to identify all relevant publications. RESULTS: MASC is an unusual and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical, and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. Many cases of MASC were discovered in archived cases previously classified as acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma not otherwise specified. CONCLUSION: MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity.
Authors: Christopher C Griffith; Edward B Stelow; Anjali Saqi; Walid E Khalbuss; Frank Schneider; Simion I Chiosea; Raja R Seethala Journal: Cancer Cytopathol Date: 2012-12-05 Impact factor: 5.284
Authors: Justin A Bishop; Raluca Yonescu; Denise A S Batista; William H Westra; Syed Z Ali Journal: Cancer Cytopathol Date: 2012-10-05 Impact factor: 5.284
Authors: Todd M Stevens; Andra O Kovalovsky; Claudia Velosa; Qiuying Shi; Qian Dai; Randall P Owen; Walter C Bell; Shi Wei; Pamela A Althof; Jennifer N Sanmann; Larissa Sweeny; William R Carroll; Gene P Siegal; Martin J Bullock; Margaret Brandwein-Gensler Journal: Mod Pathol Date: 2015-06-19 Impact factor: 7.842
Authors: Chiara Saglietti; Marco Volante; Stefano La Rosa; Igor Letovanec; Marc Pusztaszeri; Gaia Gatti; Massimo Bongiovanni Journal: Front Med (Lausanne) Date: 2017-04-24